Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.61 |
| ▸ | DRD3 | P35462 | 8/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17613234 | 0.86 | DRD2 (0.50) | DRD2DRD3MAPK1GRM5NMT2 | |
| SCHEMBL8352318 | 0.75 | — | — | |
| SCHEMBL740117 | 0.71 | DRD2 (0.54) | DRD2DRD3MAPK1GRM5 | |
| Bromide SCHEMBL6150945 | 0.70 | DRD2 (0.48) | DRD2DRD3MAPK1GRM5 | |
| SCHEMBL3534256 | 0.70 | DRD2 (0.48) | DRD2DRD3MAPK1 | |
| Hydrochloric Acid SCHEMBL18918216 | 0.68 | DRD2 (0.47) | DRD2DRD3MAPK1GRM5 | |
| SCHEMBL13937962 | 0.67 | MAPK1 (0.47) | DRD2DRD3MAPK1GRM5FGFR1 | |
| SCHEMBL740283 | 0.67 | MAPK1 (0.47) | DRD2DRD3MAPK1GRM5NMT2 | |
| SCHEMBL1427663 | 0.67 | DRD2 (0.58) | DRD2DRD3MAPK1GRM5 | |
| SCHEMBL14970397 | 0.65 | MAPK1 (0.51) | DRD2DRD3MAPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788086-B1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2788333-B1 | 1,2,4-TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |